None listed
Conditions
Brief summary
An observational pilot study to assess the burden of subclinical gout during an acute attack and during an intercritical period through asssessment of ultrasound detected synocial hypertrophy and urine hyaluronan
Interventions
Routine drug therapy as perscribed by the treating physician. This may include agents to treat acute gout including Non steroidal anti inflammatory drugs, colchicine and corticosteroids, and prophylactic agents including allopurinol and probenicid. Each Participant will be observed at two time points, once during acute gout and onbce during intercritical gout. The timing of observation will depend on the natural history of the disease in each patient, however it would be presumed that both obser
Routine drug therapy as perscribed by the treating physician. This may include agents to treat acute gout including Non steroidal anti inflammatory drugs, colchicine and corticosteroids, and prophylactic agents including allopurinol and probenicid. Each Participant will be observed at two time points, once during acute gout and onbce during intercritical gout. The timing of observation will depend on the natural history of the disease in each patient, however it would be presumed that both observations would occur within a 12 month period. Patients will be reassessed at 2 years with repeat radiographs of joints imaged at baseline ( for clincal reasons) to look for progression of damage
Sponsors
Royal Perth Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. A diagnosis of gout based on clinical presentation ( history, examination and biochemical tests) 2. Ability to give informed consent
Exclusion criteria
1.Inability to give informed consent 2.Contraindication or unwillingness to undergo an ultrasound scan 3.Diagnosis of other inflammatory joint disorder, such as rheumatoid arthritis
Outcome results
None listed